GlassScriptPhysician profile
Ahmed U Jamaluddin
NPI 1811981319
$984.75
in general payments reported to CMS, 2019-2025
14 companies · $426 in 2025
The $426 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.81 · 2020: $136 · 2021: $104 · 2022: $82.72 · 2023: $116 · 2024: $22.23 · 2025: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $564.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $196.60 | 2020-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $161.71 | 2021-2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.26 | 2021-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $110.03 | 2019-2021 | |
| Pfizer INC. | $68.66 | 2025 | |
| Akcea Therapeutics, INC. | $64.98 | 2020 | |
| Novartis Pharmaceuticals Corporation | $49.38 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $46.39 | 2020-2023 | Breztri |
| Merck Sharp & Dohme LLC | $41.51 | 2022-2023 | Verquvo |
| Edwards Lifesciences Corporation | $33.97 | 2023 | Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $29.75 | 2022 | |
| Scpharmaceuticals INC. | $22.46 | 2025 | |
| Cardiovascular Systems INC. | $19.05 | 2019 | |
| Bardy Diagnostics, INC. | $14.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmed Jamaluddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.